

**We claim:**

1. A pharmaceutical composition comprising tirzepatide, or a pharmaceutically acceptable salt thereof; propylene glycol at a concentration from 12.0 mg/mL to 18.0 mg/mL; and dibasic sodium phosphate at a concentration from 0.67 mg/mL to 2.68 mg/mL.
2. The pharmaceutical composition as claimed in Claim 1, wherein the tirzepatide, or a pharmaceutically acceptable salt thereof, concentration is from 5 to 30 mg/mL.
3. The pharmaceutical composition as claimed in Claim 1 wherein the dibasic sodium phosphate concentration is 1.34 mg/mL.
4. The pharmaceutical composition as claimed in Claim 1 wherein the tirzepatide, or a pharmaceutically acceptable salt thereof, concentration is selected from the group consisting of 5, 10, 15, 20, 25, and 30 mg/mL.
5. The pharmaceutical composition as claimed in Claim 4 wherein the tirzepatide, or pharmaceutically acceptable salt thereof, concentration is selected from the group consisting of 10, 20, and 30 mg/mL.
6. The pharmaceutical composition as claimed in Claim 1 wherein the concentration of propylene glycol is from 14.0 mg/mL to 16.0 mg/mL.
7. The pharmaceutical composition as claimed in Claim 6 wherein the concentration of propylene glycol is 15.0 mg/mL.
8. The pharmaceutical composition as claimed in Claim 1 wherein tirzepatide, or pharmaceutically acceptable salt thereof, concentration is from 5 mg/mL to 30 mg/mL; dibasic sodium phosphate concentration is from 0.67 mg/mL to 2.68 mg/mL; and propylene glycol concentration is from 14.0 mg/mL to 16.0 mg/mL.

9. The pharmaceutical composition as claimed in Claim 8 wherein tirzepatide, or pharmaceutically acceptable salt thereof, concentration is from 5 mg/mL to 30 mg/mL; dibasic sodium phosphate concentration is 1.34 mg/mL; and propylene glycol concentration is 15.0 mg/mL.
10. The pharmaceutical composition as claimed in Claim 9 wherein the composition is presented in an automatic injection apparatus.
11. The pharmaceutical composition as claimed in Claim 1 wherein the pH of the composition is from about 6.5 to about 7.5.
12. The pharmaceutical composition as claimed in Claim 11 wherein the pH is from about 6.7 to about 7.3.

Dated this: 31<sup>st</sup> day of August, 2021

Digitally signed and filed through e-filing



SACHIN BINDAL  
OF K&S PARTNERS  
AGENT FOR THE APPLICANT(S)  
IN/PA-2560